Wells Fargo analyst Derek Archila raised the firm's price target on Celldex to $54 from $38 and keeps an Overweight rating on the shares. The firm is getting more constructive on Celldex ahead of barzo's PN readout in mid-2026. Wells believes the Street underappreciates the biological rationale, supportive Phase 1b data and the role mast-cell depletion may play in the PN itch-scratch cycle.
